» Articles » PMID: 15195320

A Non-parametric Approach to the Design and Analysis of Two-dimensional Dose-finding Trials

Overview
Journal Stat Med
Publisher Wiley
Specialty Public Health
Date 2004 Jun 15
PMID 15195320
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

This paper investigates the design and analysis of dose-finding trials with two agents. The set of doses for each agent is fixed in advance. The goal of the trial is to find the set of dose combinations with probability of toxicity closest to a pre-specified value. For each of the two agents we assume that the probability of toxicity of an agent is non-decreasing with dose when the dose of the other agent is fixed. Using this assumption we construct a new non-parametric design that operates on a two-dimensional grid of all possible dose combinations. A bivariate isotonic regression estimator of the maximum tolerated combinations is described. We conclude that the new design and the bivariate isotonic estimator are superior to the procedure where several independent dose-finding trials are run.

Citing Articles

A comparison of model-free phase I dose escalation designs for dual-agent combination therapies.

Barnett H, George M, Skanji D, Saint-Hilary G, Jaki T, Mozgunov P Stat Methods Med Res. 2024; 33(2):203-226.

PMID: 38263903 PMC: 10928960. DOI: 10.1177/09622802231220497.


Two-dimensional calibration-free odds design for phase I drug-combination trials.

Wang W, Jin H, Zhang Y, Yin G Front Oncol. 2023; 13:1294258.

PMID: 38094604 PMC: 10718486. DOI: 10.3389/fonc.2023.1294258.


Evaluation of phase I clinical trial designs for combinational agents along with guidance based on simulation studies.

Wang S, Sayour E, Lee J J Appl Stat. 2023; 50(9):2055-2078.

PMID: 37378271 PMC: 10291942. DOI: 10.1080/02664763.2022.2105827.


Concurrent dose-finding of a novel cancer drug with and without a second agent.

Wages N, Saleh R, Braun T J Clin Transl Sci. 2023; 7(1):e126.

PMID: 37313388 PMC: 10260343. DOI: 10.1017/cts.2023.542.


A clinical phase I dose-finding design with adaptive shrinking boundaries for drug combination trials.

Li Z, Xu Z, Zhang A, Qi G, Li Z BMC Med Res Methodol. 2023; 23(1):57.

PMID: 36864387 PMC: 9979534. DOI: 10.1186/s12874-023-01867-y.